NDAC Meeting On Actual-Use Trials Scheduled For September
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee will convene Sept. 25 to "consider issues related to the analysis and interpretation of consumer behavior studies conducted to support marketing" of OTCs
You may also be interested in...
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
Actual Use, Label Comprehension Guidances Slated For 2006
Guidances under development in 2006 reflect FDA's interest in improving the quality of Rx-to-OTC switch submissions